Results 171 to 180 of about 109,382 (263)

Inhibition of the MER tyrosine kinase ameliorates pulmonary fibrosis by suppressing macrophage M2 polarisation and osteopontin signalling

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose The MER proto‐oncogene tyrosine kinase (MERTK) has been implicated in the pathogenesis of pulmonary fibrosis (PF), and MERTK inhibition has been shown to ameliorate PF. However, the mechanisms remain unclear. Here, we have investigated how MERTK inhibition attenuates bleomycin (BLM)‐induced PF in mice and to elucidate the ...
Juan Li, Xiangsheng Yang, Xiao Xiao Tang
wiley   +1 more source

The Inv(16) Oncogene CBFB::MYH11 is Required for the Survival of Leukemia Cells in the Blood and Spleen, but not the Bone Marrow. [PDF]

open access: yesOncogene
Panda S   +12 more
europepmc   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

open access: yesCancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

open access: yesCancer Science, EarlyView.
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda   +9 more
wiley   +1 more source

Genetic Engineering of Tumor‐Infiltrating Lymphocytes (TIL) via a T‐Editor Platform to Enhance Anti‐Tumor Activity

open access: yesCancer Science, EarlyView.
A rapid and efficient CRISPR‐mediated gene editing platform for TIL engineering identified FAM84B as a novel potential target to enhance antitumor activity and pioneered the use of CBE to generate FAM84B loss‐of‐function TIL with enhanced antitumor activity.
Fenge Li   +13 more
wiley   +1 more source

TRIM59 Drives Bladder Cancer Progression Through E3 Ligase‐Dependent K48‐Linked Degradation of PTRF

open access: yesCancer Science, EarlyView.
Schematic model of TRIM59‐driven BLCA progression through K48‐linked ubiquitination and proteasomal degradation of PTRF, leading to AKT activation and c‐Myc upregulation. ABSTRACT Tripartite motif‐containing 59 (TRIM59) is an E3 ubiquitin ligase implicated in multiple malignancies, but its role in bladder cancer (BLCA) remains incompletely understood ...
Junlin Gan   +9 more
wiley   +1 more source

Melanoma of the Scalp Harboring a Novel AGFG1::ERBB4 Fusion: A Case Report With Clinicopathologic and Genomic Characterization. [PDF]

open access: yesGenes Chromosomes Cancer
Cao X   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy